References
- Bork K, Wulff K, Steinmuller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. 2018;73(2):442–450.
- Bafunno V, Firinu D, D‘Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. 2018;141(3):1009–1017.
- Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–616.
- Kaplan AP, Joseph K. Pathogenesis of hereditary angioedema: the role of the Bradykinin-forming cascade. Immunol Allergy Clin North Am. 2017;37(3):513–525.
- Farkas H. Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother. 2013;14(5):571–586.
- Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131–1140.
- Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108–2121.
- Aygoren-Pursun E, Bygum A, Grivcheva-Panovska V, et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. N Engl J Med. 2018;379(4):352–362.
- Kalfus I, Qs MA. Potency, selectivity, and exposure evaluation of atn-249, a new oral kallikrein inhibitor for hereditary angioedema. J Allergy Clin Immunol. 2017;139(2):AB378.
- Overview of KalVista‘s drug discovery. [Cited 2018 Dec 20]. Available from: http://www.kalvista.com/discovery-overview.html.
- Li Z, Partridge J, Silva-Garcia A, et al. Structure-guided design of novel, potent, and selective macrocyclic plasma kallikrein inhibitors. ACS Med Chem Lett. 2017;8(2):185–190.
- Interim results of the drug development program of Verseon Corporation. [Cited 2018 Dec 20]. Available from: http://www.verseon.com/media-1/news/154-interim-results-2017.
- Bhattacharjee G, Revenko AS, Crosby JR, et al. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther. 2013;23(3):175–187.
- Cao H, Biondo M, Lioe H, et al. Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. J Allergy Clin Immunol. 2018;142(4):1355–1358.
- Liu J QJ, Cooley B, et al. Reduction of hepatic factor XII expression in mice by ALN-F12 inhibits thrombosis without increasing bleeding risk - presentation held at ISTH 2017. [Cited 2018 Dec 20]. Available from: http://www.alnylam.com/wp-content/uploads/2017/07/ALN-F12-ISTH2017-Presentation-Final.pdf.
- Akinc A, Lj QJ. An investigational RNAi therapeutic targeting factor XII (ALN-F12) for the treatment of hereditary angioedema. American Academy of Allergy, Asthma, and Immunology Annual Meeting; 2016 Mar 4–7; Los Angeles, CA. J Allergy Clin Immunol; 2016.
- Qiu T, Chiuchiolo MJ, Whaley AS, et al. Gene therapy for C1 esterase inhibitor deficiency in a murine model of hereditary angioedema. Allergy. 2018.